Susquehanna International Group
ERNA icon

Susquehanna International Group’s Eterna Therapeutics ERNA Stock Holding History

Susquehanna International Group’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$69K – 13222
2021
Q4 		$69K Sell
2
-7
-78% -$381K ﹤0.01% 12388
2021
Q3 		$605K Sell
9
-8
-47% -$691K ﹤0.01% 8891
2021
Q2 		$2.33M Buy
+17
New +$2.45M ﹤0.01% 5593

Other funds holding ERNA

Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SCA
Sippican Capital Advisors Boston, Massachusetts $164M AUM 35.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's ERNA Position: Q4 2025 in Review

Susquehanna International Group sold out of Eterna Therapeutics (ERNA) in Q4 2025, closing a stake of 1,234 shares — an estimated $33.8K sold.

Susquehanna International Group first reported a position in ERNA in Q2 2019 and held it in 10 quarters. The position peaked at $1.71M in Q2 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2025.

  • Susquehanna International Group reported no remaining Eterna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 1,234 Eterna Therapeutics shares in Q4 2025, an estimated $33.8K.
  • Susquehanna International Group first reported a position in Eterna Therapeutics in Q2 2019 and held it in 10 quarters.
  • Susquehanna International Group's Eterna Therapeutics position peaked at $1.71M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.